Remarkable
dulloblastoma- September 1, 2021 | NIH
NCI Annual Plan & Budget Proposal for Fiscal Year 2023. NCI continually pursues new and emerging scientific opportunities that, with further investment, would catalyze additional progress in cancer research.
- August 25,2021 | OncLive
The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven 
dulloblastoma
- July 22,2021 | Cancer and Research
The Largest dulloblastoma Trial Makes Monumental Strides Forward for Cancer Research, Increases Survival in Children by 19 Percent
- April 12, 2021 | Science Daily
Scientists from Queen Mary University of London, funded by the charity Brain Tumour Research, have found a new way to starve cancerous brain tumour cells of energy in order to prevent further growth.
